Inflammaging: Biomarkers, Causes and What Helps

It is not a disease diagnosed by one number. It is a scientific concept linking inflammation and age. Learn what can be measured, what it means and what genuinely helps.

If a blood test shows high C-reactive protein, that does not automatically mean you have “inflammaging”. The term describes an age-related biological phenomenon, not a disease with a positive or negative test. It cannot explain fatigue, brain fog, pain or lifespan on its own.

The idea still matters. As we age, the immune system and other tissues can maintain a low-level chronic inflammatory signal. That signal is associated with frailty and several diseases, but measuring and interpreting it takes more care than reading a red number on a report.

This guide separates three questions: what inflammaging is, what blood tests can add and which decisions have evidence. For a broader overview, see our guide to longevity biomarkers.

Evidence review: 29 August 2026. We reviewed foundational work, a 2026 immunology update, clinical trials and reviews of exercise, sleep and biomarkers. This is an editorial review and does not turn inflammaging into a validated clinical diagnosis.

The essentials in one minute

Inflammaging is a research concept describing low-grade chronic inflammation associated with advanced age.
No symptom, test or universal cut-off diagnoses it.
High hsCRP is non-specific: it signals inflammation, not its source.
IL-6, TNF-α and suPAR may add knowledge, but they are not a standard panel for every healthy person.
The clinical goal is to find and treat specific causes or risks, not chase an abstract score.
Exercise, a Mediterranean pattern, not smoking, sleep and cardiometabolic care help through broad benefits, not by promising to “switch off” ageing.

What inflammaging means

Acute inflammation is a defence tool. It responds to infection, wounds or injury and supports repair. Inflammaging describes something different: persistent, systemic, low-intensity activation seen more often in advanced age.

Franceschi and colleagues popularised the term to explain the overlap between immune ageing and inflammation. A 2026 review describes it as dynamic and multifactorial. It involves changes in immune cells, less efficient clearance of cellular waste, inflammatory cell death and signals from non-immune tissues, including some senescent cells.

There is no single switch. Persistent infections, smoking, inactivity, visceral adiposity, metabolic disease, oral health, sleep, stress and environmental exposure can combine differently in each person. Even some centenarians show inflammatory signals but appear to buffer their downstream effects more effectively. Healthy ageing does not mean zero inflammation, which would be incompatible with normal defence.

Not all chronic inflammation is inflammaging

Situation	What it describes	What to do
Acute inflammation	A temporary response to infection, injury or a procedure	Interpret the result within that episode
Disease-related inflammation	A signal linked with a specific cause such as infection, autoimmunity or metabolic disease	Diagnose and treat the cause
Inflammaging	A research framework for low-grade inflammation associated with age	Do not turn it into a diagnosis of exclusion or a marketing label

This distinction prevents a common mistake: assigning every high result to “inflammatory ageing” without checking for infection, dental disease, autoimmunity, recent injury or a treatable cardiometabolic risk.

Why it matters for health

Systemic chronic inflammation is associated with cardiovascular disease, type 2 diabetes, kidney disease, some cancers, neurodegenerative disorders and frailty. Association does not mean one cytokine causes them all. These processes influence one another and vary with genetics, environment, age and disease.

CANTOS provides an important piece of causal evidence. It enrolled 10,061 people with previous myocardial infarction and hsCRP of at least 2 mg/L. The canakinumab dose that met the statistical threshold reduced relative risk of the composite cardiovascular outcome by 15% versus placebo without lowering lipids. It also increased fatal infections and did not reduce all-cause mortality. The right conclusion is that one inflammatory pathway can be treated in a highly selected population, not that everyone should take an anti-inflammatory drug to live longer.

There are plausible mechanisms and consistent associations in muscle, brain and metabolism, but no cytokine panel replaces ordinary assessment of strength, function, blood pressure, lipids, glucose, kidney function, symptoms and history.

Does it have symptoms?

There is no specific clinical picture. Fatigue, pain, slow recovery, brain fog or unrefreshing sleep are real, but they may arise from anaemia, sleep apnoea, depression, infection, thyroid disease, medication effects and many other causes. Calling them “inflammaging symptoms” can delay a useful diagnosis.

Seek assessment for persistent symptoms, fever, unexplained weight loss, night sweats, new joint pain, lasting bowel changes or repeatedly high inflammatory markers. The goal is not to confirm a label but to understand what is happening.

What biomarkers can tell you

There is no reference blood test for diagnosing inflammaging. These tests answer different questions:

Test	What it can add	Main limitation
hsCRP	A sensitive signal of systemic inflammation and cardiovascular-risk context	It does not identify the cause or diagnose inflammaging
Conventional CRP	Measures the same protein over a range suited to more marked inflammation	It is not part of a blood count and does not identify the cause either
ESR and fibrinogen	Additional context for specific clinical questions	They are non-specific and influenced by several factors
IL-6 and TNF-α	Research or specialist assessment of inflammatory pathways	Pre-analytical variation and no universal cut-offs for this use
suPAR	An emerging marker of chronic immune activation	Initial ageing research, not a standard diagnostic test

The Dunedin suPAR study followed a cohort born in 1972-1973 and found associations with pace of ageing, function and cognitive change at age 45. Its authors described “initial support” for research utility. That is promising, but it does not prove suPAR is more specific than hsCRP or establish one price, universal cut-off or treatment.

Epigenetic clocks do not diagnose inflammation either. Some include proxies related to risk, but a high epigenetic age does not confirm inflammaging and a low one does not rule it out.

How to read high hsCRP without panicking

Ask about context. Recent infection, injury, surgery or inflammatory disease may shift the result.
Do not diagnose from one number. A clinician can decide whether and when repeating it is useful.
Review common, treatable causes. Smoking, visceral adiposity, periodontal disease, inactivity and metabolic risk deserve attention.
Connect the result to the clinical question. hsCRP may refine cardiovascular risk in selected settings, but it does not replace blood pressure, ApoB or LDL-C, glucose and history.
Avoid treating the number alone. Lowering one marker does not guarantee less disease or a longer life.

What genuinely helps

Adapted physical activity

A 2026 network meta-analysis included 55 randomised trials and 3,516 middle-aged and older adults. Resistance training showed the strongest CRP reduction; aerobic training showed the best signals for IL-6 and TNF-α. This does not make one mode a universal prescription. The mix should reflect capacity, injuries, disease and adherence.

The most important benefit of exercise is not one biomarker: it improves strength, cardiorespiratory fitness, insulin sensitivity, blood pressure, mobility and wellbeing.

A Mediterranean dietary pattern

The corrected republication of PREDIMED studied 7,447 people aged 55 to 80 at high cardiovascular risk. Mediterranean groups receiving extra-virgin olive oil or nuts had fewer cardiovascular events than the control group. Randomisation deviations prompted withdrawal and republication of the original paper, context that belongs in an honest summary.

The result supports a pattern rich in vegetables, legumes, fruit, nuts, whole grains, olive oil and fish, not a superfood list or generic supplement doses. Practical implementation belongs in our anti-inflammatory nutrition guide.

Sleep, smoking and cardiometabolic health

A review of 72 studies involving more than 50,000 people linked sleep disturbance with higher CRP and IL-6. Experimental sleep deprivation or restriction, however, did not consistently raise CRP, IL-6 or TNF-α. It is therefore inaccurate to claim that one poor night inevitably raises every cytokine.

Better sleep still matters, as do smoking cessation, sensible alcohol intake, treatment of sleep apnoea, diabetes or hypertension, and addressing excess adiposity when present. These are concrete clinical goals, not a magic protocol for “switching off” NF-κB.

Supplements and treatment: indication first

There is no universal supplement for inflammaging. Omega-3, magnesium, curcumin or vitamin D may have indications, doses, interactions and effects that differ by person. One biomarker does not justify taking high-dose EPA+DHA, chasing a particular omega-3 index or combining products without reviewing diet, medication and bleeding risk.

Nor is there validation for prescribing intravenous NAD, ozone therapy, plasmapheresis, intense cold exposure or senolytics from high hsCRP, IL-6 or suPAR. CANTOS shows why precision matters: a drug may reduce events in a specific population and still cause harm. Useful medicine treats a defined cause or risk.

How we approach it in a Progevita assessment

A careful assessment does not begin by selling a panel. It starts with symptoms, history, medication, sleep, activity, oral health, body composition and cardiometabolic risk. Tests are then chosen only when they can change a safe decision.

If a marker is high, the question is not “which longevity therapy lowers it?” but “which plausible causes should we confirm or rule out?”. The answer may be to repeat, investigate disease, adjust treatment, improve habits or add no intervention at all.

Frequently asked questions about inflammaging

What exactly is inflammaging?

It is a scientific concept describing a chronic, systemic, low-grade rise in some inflammatory signals associated with advanced age. It is multifactorial and is not the same as any inflammation or one specific disease.

Is inflammaging a diagnosable disease?

There is no universal clinical diagnosis of inflammaging and no single panel that confirms it. It is studied as a biological process. In practice, clinicians investigate specific diseases, risks and causes of persistent inflammation.

Does inflammaging have its own symptoms?

It has no specific symptom pattern. Fatigue, brain fog, pain or slow recovery can have many causes and cannot diagnose inflammaging. New or persistent symptoms deserve clinical assessment.

Which blood test is best for measuring it?

There is no reference test. hsCRP can add context about systemic inflammation and cardiovascular risk, but it is non-specific. IL-6, TNF-α and suPAR are mainly research or selected-use markers and have no universal cut-offs for diagnosing inflammaging.

What does a high hsCRP result mean?

It means more C-reactive protein is circulating, not what caused it. Recent infection, injury, inflammatory disease, smoking, adiposity and other factors can raise it. It should be read alongside symptoms, history and, when appropriate, repeat testing.

Can inflammaging be reduced?

Causes and factors linked with chronic inflammation, such as smoking, inactivity, excess adiposity or poorly controlled disease, can be addressed. That improves health even if one biomarker does not change. Claiming complete reversal would go beyond the evidence.

Which habits have the strongest evidence?

Adapted physical activity, a Mediterranean dietary pattern, not smoking, sufficient sleep and treatment of cardiometabolic risks have broad clinical benefits. No routine or percentage reduction is guaranteed for everyone.

Do NAD, ozone, plasmapheresis or senolytics treat inflammaging?

They are not validated treatments for a general diagnosis of inflammaging. An isolated inflammatory result should not prescribe these interventions. The priority is to find the cause and use treatments with proven clinical benefit for that situation.

References

This article is educational and does not replace individual medical assessment. An inflammatory marker may have causes requiring specific diagnosis and treatment.

Have a blood result you cannot place in context? In a pre-consultation with the medical team, we can organise the question before adding more tests or treatments. Sometimes better measurement helps; sometimes looking for one specific cause matters more.